Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04242667 · ClinicalTrials.gov registry record · NA
Penn Biobank Return of Research Results Program
A NA study, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- NA
- Development phase
- 260
- Enrollment target
NCT04242667 is a NA study that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 260 participants.
The verdict
NCT04242667, a NA study, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- NA
- Development phase
- 260 participants
- Enrollment target
Study Summary
The overall goal of the proposed research is to assess the feasibility of a randomized study evaluating the non-inferiority of an electronic Health (e-Health) delivery alternative (e.g. private web portal) as compared to return of actionable genetic research results with a genetic counselor.
Interventions
- BEHAVIORAL e-Health (web-based) disclosure portal
- BEHAVIORAL Provider mediated disclosure
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 260 participants |
| Start Date | 2020-03-01 |
| Est. Completion | 2023-08-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04242667
The ClinicalTrials.gov registry entry for NCT04242667 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 260 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which e-Health (web-based) disclosure portal is the first listed.
NCT04242667 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04242667 about?
NCT04242667 is a clinical study titled "Penn Biobank Return of Research Results Program". The overall goal of the proposed research is to assess the feasibility of a randomized study evaluating the non-inferiority of an electronic Health (e-Health) delivery alternative (e.g. private web portal) as compared to return of actionable genetic research results with a genetic counselor.
What is the current status of trial NCT04242667?
This trial is currently completed. It is a NA study. The enrollment target is 260 participants. The study started on 2020-03-01. Estimated completion is 2023-08-01.
What interventions are being tested in trial NCT04242667?
The interventions under investigation include: e-Health (web-based) disclosure portal (BEHAVIORAL), Provider mediated disclosure (BEHAVIORAL).
Who is sponsoring clinical trial NCT04242667?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.